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The number of survivors after allogeneic hematopoietic stem cell transplantation (HSCT) continues to in-
crease, yet their survivorship experience has not been fully characterized. This study examines the health
status and health-related quality of life (HRQL) of HSCT survivors. The aims of the study were to: (1) explore
the baseline and change over time in these health outcomes, and (2) characterize subgroups experiencing
adverse outcomes. In this longitudinal study, adults who survived >3 years from date of allogeneic HSCT
completed a series of patient-reported outcome measures annually, including measures of health status,
HRQL, and symptoms. Data were analyzed using hierarchical linear modeling. Subjects (N ¼ 171) were on
average 44 (13.5) years of age and primarily male (62.6%); 40% were Hispanic. Mean scores for physical and
mental health and HRQL were preserved relative to population norms. Hierarchical linear modeling revealed
no signiﬁcant change in the mean trajectories of these outcomes, although signiﬁcant between-individual
variability was observed. When controlling for demographic and clinical factors, physical symptom distress
negatively affected all outcomes. The impact of symptom distress on physical health varied based on time
since HSCT; impairment in physical health was greatest in survivors experiencing high symptom distress and
who were within the ﬁrst decade post transplantation. Extended treatment with systemic immunosup-
pressive therapy also predicted inferior physical health. These ﬁndings suggest that patient-centered out-
comes are preserved relative to normative values and are generally stable after allogeneic HSCT, although
survivors with persistent symptoms and those receiving systemic immunosuppression experience impair-
ments in health status and HRQL.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION versus-host disease (cGVHD) have played a signiﬁcant role
Allogeneic hematopoietic stem cell transplantation (HSCT)
has become a curative treatment for patients with a wide
variety of diseases [1,2], with approximately 25,000 alloge-
neic HSCTs performed annually worldwide [3]. The increasing
number of stem cell transplantations performed reﬂects a
greater availability of donors from acceptable transplant
sources (umbilical cord, unrelated donors, haploidentical
donors) and the breadth of indications for this treatment. The
availability of reduced-intensity conditioning regimens has
also extended this treatment option to individuals who are
older and those with comorbidities. At the same time, im-
provements in human leukocyte antigen (HLA) matching,
prevention, and treatment of post-transplantation infections,
and more effective management of acute and chronic graft-dgments on page 394.
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13.12.001in extending HSCT survivorship [4]. Although survivorship
after life-threatening illness is a beneﬁt, at the same time, late
effects of HSCT including cGVHD, opportunistic infections,
and the management of minimum residual disease, are
challenges that can be difﬁcult to manage and contribute to
the need for specialized long-term follow-up [5].
Beyond the clinical aspects of recovery, survivorship also
entails a reintegration back into domestic and professional
roles and meaningful routines and activities that generate a
sense of well-being and quality of life. The assessment of
health-related quality of life (HRQL) includes biological fac-
tors along with functional status, symptom experience, gen-
eral health perceptions, and overall quality of life [6]. Several
recent reviews have examined HRQL after transplantation
[7,8], including 1 focused speciﬁcally on the experiences of
long-term survivors of allogeneic HSCT [9]. Although current
evidence suggests that most survivors experience a relatively
good HRQL when compared with healthy populations or to
other chronically ill populations, a subset of survivors report
impaired physical or emotional function [10-13]. MajorSociety for Blood and Marrow Transplantation.
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variation in HRQL outcomes arewell described [14], including
the unique complications and late effects, such as cGVHD and
infections associated with prolonged immunosuppression
therapy, which substantially shape the recovery experienced
by long-term survivors [15-17]. However, no prior studies
have evaluated physical and mental health status and HRQL
longitudinally in a diverse sample of allogeneic HSCT re-
cipients during a period of extended survival. This study
characterizes patterns of recovery according to health status
and HRQL in a diverse population of survivors 3 years after
allogeneic HSCT and identiﬁes predictors of impairment in
these outcomes.
MATERIALS AND METHODS
Study Design and Participants
The design of this prospective longitudinal study has been previously
described [18]. This study was approved by the National Heart, Lung and
Blood Institute intramural Institutional Review Board and all patients pro-
vided written informed consent before participation. Patients who were
3 years after ﬁrst allogeneic HSCT (after receiving either a myeloablative [19]
or reduced-intensity [20-22] conditioning regimen) at the National In-
stitutes of Health Clinical Center were accrued consecutively. Eligible study
participants were at least 18 years old, carried a life expectancy of at least
6 months, and spoke and read English or Spanish. Those with a life expec-
tancy less than 6 months and individuals who had undergone a second
allogeneic HSCT procedure were excluded from participation. Those who
agreed to join the study completed a survey packet annually within 60 days
of their annual clinical follow-up.
Study Procedures
Paper and pencil questionnaires, which took approximately 45 minutes
to complete, were administered to outpatients in a private area. In some
instances, the questionnaires were mailed with instructions for completion
and a postage-paid return envelope. If the questionnaires were not returned
within 2 weeks, a follow-up phone call was made to conﬁrm receipt of the
questionnaires and respond to any questions or concerns about completion.
Permission to contact participants by phone and e-mail was obtained during
the consenting process.
Measures
Physical and mental health status were measured using the Medical
Outcomes Study Short Form 36-Version 2 [23]. The Short Form-36 is a 36-
item self-report measure of physical and mental health, evaluating 8 sub-
scales including physical functioning, physical role functioning, emotional
role functioning, social functioning, bodily pain, mental health, vitality, and
general health. In addition to the individual subscale scores, a Physical
Component Score (PCS) and Mental Component Score (MCS) are computed
through aggregation of the subscales. To facilitate comparison with US
healthy population values, summary and subscale scores were transformed
to a T-score metric, with a mean of 50 and standard deviation of 10. Higher
scores indicate better outcomes [23]. Summary scores that are 3 or more
points above or below the norm-based score of 50, the minimum important
difference indicating clinical relevance, are considered outside the average
range for the US healthy population. The Short Form-36 was translated into
Spanish through the International Quality of Life Assessment Project. Strong
evidence of internal consistency reliability and construct validity has been
documented in Spanish-speaking samples [24-27].
HRQL was measured with the Functional Assessment of Cancer Ther-
apyeGeneral Version 4 (FACT-G) [28]. The FACT-G is a 27-item self-report
cancer-speciﬁc quality of life questionnaire. Scores are summed to yield a
FACT-G Total Score, which can range from 0 to 108. Higher scores indicate
better HRQL. The US healthy population value for the FACT-G total score is
80.1 (18.1) and a 5-point difference is considered clinically meaningful
[29]. The Spanish version of the FACT-G (version 4) has demonstrated
construct validity and evidence of strong internal consistency reliability
[30,31].
Physical symptom distress was assessed with the physical symptom
distress scale (PSDS) of the Rotterdam Symptom Checklist [32]. The PSDS
consists of 23 items evaluating the bother experienced in the past 30 days
from a range of physical symptoms. Total PSDS scores range from 23 to 92;
higher scores indicate more symptom distress. The PSDS raw scores were
linearly transformed into scores on a 100-point scale; previously published
data [32] suggest 3 cut-points that may be used to aid interpretation. Thus, a
transformed score of <10 was considered “low” (eg, healthy population), 10to 15 as “mild/moderate” (ie, disease free population, newly diagnosed), and
> 15 as “high” (ie, active treatment, high symptom burden cancer type). The
Spanish version of the Rotterdam Symptom Checklist has demonstrated
strong internal consistency reliability and construct validity in Spanish-
speaking cancer patients [10].
Demographic (age, gender, race, ethnicity, years post transplantation,
country of residence, marital status, educational attainment, and employ-
ment) and clinical (intensity of conditioning, HLA compatibility, stem cell
source, primary disease, stage of disease, and comorbidity score) variables
were collected at time of study enrollment. Transplantation risk status was
classiﬁed based on an expanded version of published guidelines [33] to yield
3 risk categories based on type of malignancy/disease and stage at the time
of transplantation: standard, intermediate, high/very high. Comorbidities at
time of transplantation were retrospectively scored using the hematopoietic
stem cell transplantationecomorbidity index [34], and categorized accord-
ing towhether 0,1 to 2, or3 comorbidities were present. Several additional
clinical variables were also collected annually and modeled as time-varying
factors. These variables included Eastern Cooperative Oncology Group
performance status, evidence of disease, current treatment with systemic
immunosuppression, and physical symptom distress. Evidence of disease
was coded based on molecular, hematopathologic, or radiographic evidence
of disease and whether treatment had been administered for their primary
disease in the past year. Only subjects in complete remission and who
had not received treatment for their primary disease in the past year were
coded as “no evidence of disease.” If a subject was receiving any immuno-
suppressive therapy, including single-agent prednisone, they were classiﬁed
as positive for the presence of immunosuppression (compared to none)
[17,35-37].
Statistical Analysis
Descriptive statistics were used to describe clinical and demographic
characteristics of subjects and to summarize health status, HRQL, and
physical symptom distress scores at each year after allogeneic HSCT. Hier-
archical linear modeling (HLM) was used to analyze within-individual
(level-1) and between-individual (level-2) changes. The main goal of HLM
models was to examine changes over time in longitudinal data, and there-
fore time was included in all models.
For each of the 3 outcomes variables (PCS, MCS, and FACT-G) HLM was
performed in 2 steps. First, 3 unconditional models were speciﬁed: un-
conditional means model (no time effect), unconditional linear model
(linear time effect), and unconditional quadratic model (quadratic time
effect). The main purpose of ﬁtting the unconditional means models is to
estimate level-1 and level-2 variance components. This allows for a deter-
mination of whether signiﬁcant between-individual variability exists in the
trajectories for physical health, mental health, or HRQL, which may be
accounted for by level-2 covariates [38]. If the level-2 variance components
are signiﬁcant, suggesting substantial between-individual variability in the
intercept or trajectory, demographic and clinical variables signiﬁcant in the
uncontrolled model, along with the baseline clinical factors, are then
examined in an adjusted model. The deviance goodness-of-ﬁt test was used
to compare the model ﬁt of the linear and quadratic time effect models.
Subsequently, each time-invariant (age, gender, education, ethnicity,
marital status, disease risk status, conditioning type, and hematopoietic
stem cell transplantationecomorbidity index category) and time-varying
(evidence of disease, treatment with systemic immunosuppression, and
physical symptom distress) covariate was tested one by one to see if it alone
was a signiﬁcant level-2 predictor of the outcome. Two HLM models were
speciﬁed to sequentially investigate the association of the covariates with
the 3 outcomes. Model 1 included the following demographic and baseline
clinical variables: age, gender, ethnicity, transplantation risk status, co-
morbidity, and conditioning type. The ﬁnal model (model 2) included all
other time-invariant and time-varying variables that were signiﬁcant at the
intercept or linear term in the individual models, in addition to the cova-
riates from model 1.
All models were estimated using full information maximum likelihood
estimation. The unstructured covariance matrix was used for random in-
tercepts and slopes in each model. A P value <.05 indicated statistical sig-
niﬁcance. All data analyses were performed using SAS 9.3 [39].
RESULTS
Study Participants
Beginning in August 2005, 227 HSCT survivors were
screened and 173 agreed to participate and completed the
enrollment (baseline) survey. Fifty-four patients were not
enrolled because of lack of interest (n ¼ 10), clinical acuity/
second HSCT (n¼ 16),<18 years of age (n¼4) limited literacy,
or speaking a language other than English or Spanish
Table 1
Demographic and Clinical Characteristics
Demographic Characteristics* All Participants
N ¼ 171
Age, mean (SD), yry 44.5 (13.45)
Range 19-76
Sex (male) 107 (62.6)
Race/Ethnicity
Hispanic 69 (40.4)
Non-Hispanic
White 65 (38.0)
Asian 18 (10.5)
Black 15 (8.8)
Mixed 4 (2.3)
Residencyy,z
Always in United States 68 (40.7)
Stayed in United States after HSCT 42 (25.1)
Left United States after HSCT 57 (34.1)
Marital Status (married)x 109 (64.1)
Educationk,#
Through high school graduate 48 (28.4)
Some college/associate’s degree 43 (25.4)
Bachelor’s degree 35 (20.7)
Graduate 43 (25.4)
Employmentk
Full-time 69 (40.8)
Part-time 37 (21.9)
Student 11 (6.5)
Not working 52 (30.8)
Clinical Characteristics Pre-Transplantation
HCT-CI Score
0 score 55 (32.1)
1 or 2 score 55 (32.1)
3 score 61 (35.8)
Transplantation risk status
Low 92 (53.8)
Intermediate 35 (20.5)
High/very high 44 (25.7)
Primary disease
Acute leukemia 33 (19.3)
Chronic leukemia 62 (36.3)
Lymphoma/MM 39 (22.8)
MDS 17 (9.9)
Nonhematological malignancy 14 (8.2)
Solid tumor 6 (3.5)
Conditioning regimeny
RIC 76 (44.4)
Myeloablative 95 (55.6)
Stem cell source
Peripheral blood 166 (97.1)
Bone marrow 5 (2.9)
HLA compatibility
Matched sibling 169 (98.8)
Syngeneic 2 (1.2)
Clinical characteristics Study enrollment
Evidence of diseasey,z,{ 34 (19.9)
Disease status
CR 142 (83.0)
PR/stable/MRD/molecular relapse 17 (9.9)
PD/hematologic relapse 12 (7.0)
Receiving active treatment 19 (11.1)
Immunosuppression intensity
None 114 (66.7)
Mild 7 (4.1)
Moderate 40 (23.4)
High 10 (5.8)
cGVHD severity
None 97 (56.7)
Mild 43 (25.1)
Moderate 26 (15.2)
Severe 5 (2.9)
ECOG performance status
Grade 0 138 (70.8)
Grade 1 32 (18.7)
Grade 2 1 (0.6)
(continued)
Time since HSCT, mean (SD), yr
Range
Median
5.19 (2.93)
3-16
4.0
MM indicates multiple myeloma; MDS, myelodysplastic syndrome; RIC,
reduced-intensity conditioning; HLA, human leukocyte antigen; CR, com-
plete remission; PR, partial remission; MRD, minimal residual disease; PD,
progressive disease; ECOG, Eastern Cooperative Oncology Group; HCT-CI,
hematopoietic stem cell transplantationecomorbidity index; SD, standard
deviation; HSCT, hematopoietic stem cell transplantation; cGVHD, chronic
graft-versus-host disease.
Data presented are n (%) unless otherwise indicated.
Hispanic subjects were signiﬁcantly younger, less educated, had less evi-
dence of disease and more likely to have residency outside of the United
States and to have a myeloablative HSCT.
* At study enrollment.
y P < .001.
z n ¼ 167.
x n ¼ 170.
k n ¼ 169.
{ Of those classiﬁed as having evidence of disease, 5 (14.7%) had achieved
a CR but were continuing a course of disease speciﬁc treatment.
# P < .01.
Table 1
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N ¼ 171
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second year questionnaires (n ¼ 154), third year question-
naires (n ¼ 106), fourth year questionnaires (n ¼ 73), ﬁfth
year questionnaires (n ¼ 53), and sixth year questionnaires
(n ¼ 1) until study closure in December 2010 (n ¼ 139
remained on study). Attrition was due to death (n ¼ 17),
participant withdraw/lost to follow-up (n ¼ 10), and clinical
acuity/second HSCT (n ¼ 7).
Adult participants (n ¼ 171) with complete enrollment
data were primarily male (62.6%), married (64.1%), and
racially/ethnically diverse (40.4% Hispanic, 10.5% Asian, and
8.8% Black) (Table 1). At time of enrollment, subjects were on
average 5.19  2.93 years after a myeloablative allogeneic
HSCT (55.6%) from a matched sibling donor (98.8%) for leu-
kemia (55.6%). The majority of participants were in a com-
plete remission (83%) (Table 1).
Unadjusted baseline means for PCS, MCS, and FACT-G in
the pooled sample and for subgroups who were 3, 4 to
6 years, or 7 or more years post transplantation were
compared to US healthy population values (Table 2). In the
pooled sample, mean scores were descriptively within the
expected range (norm-based scores, 47 to 53) for PCS and
MCS. At enrollment, approximately one third of the sample
reported PCS (n ¼ 65, 38%) and MCS (n ¼ 59, 34.5%) scores
that suggest impairments that were clinically relevant (47).
Similarly, FACT-G scores consistently exceeded the popula-
tion mean, with slightly less than one ﬁfth of the re-
spondents (n ¼ 34, 19.9%) reporting scores suggesting
clinically relevant impairment (75.1). The mean PSDS
scores were within a range comparable to cancer patients
receiving active treatment (>15).
Physical Health
The unconditional PCS model demonstrated no signiﬁ-
cant change in the trajectory of physical health (P  .05)
although the variance components (intercept, linear rate of
change, within-person variability) were signiﬁcant (Table 3).
In the ﬁnal model (model 2), 3 time-varying predictors (ev-
idence of disease, intensity of immunosuppression, and
physical symptom distress) explained additional variability
Table 2
Patient-Reported Outcome Measures
Outcome All Participants* (N ¼ 171) 3 Years Post HSCT (n ¼ 78) 4 to 6 Years Post HSCT (n ¼ 50) 7 þ Years PostHSCT (n ¼ 43)
SF-36y
Physical function 46.97 (10.08) [14.94-57.03] 47.76 (8.26) [27.57-57.03]z 45.22 (12.35) [14.94-57.03]z 47.06 (10.27) [25.47-57.03]z
Role physical 45.67 (10.04) [17.67-56.85] 46.28 (9.07) [20.12-56.85]z 43.51 (11.72) [17.67-56.85]z 46.42 (9.49) [22.57-56.85]z
Bodily pain 51.27 (9.67) [19.86-62.12] 51.01 (8.82) [29.15-62.12]z 50.89 (11.00) [19.86-62.12]z 52.15 (9.61) [29.15-62.12]z
General health 47.68 (10.44) [21.95-63.90] 48.38 (9.85) [21.95-63.90]z 46.10 (11.82) [23.38-63.90]z 48.18 (9.91) [26.90-63.90]z
Vitality 53.22 (9.61) [23.99-70.82] 53.53 (9.67) [30.24-70.82]z 52.41 (10.10) [23.99-70.82]z 53.06 (8.92) [33.36-70.82]z
Social function 47.75 (10.04) [13.22-56.85] 46.80 (10.73) [18.67-56.85]z 47.28 (10.82) [13.22-56.85]z 49.58 (7.49) [29.58-56.85]z
Role emotional 45.50 (10.98) [9.23-55.88] 45.65 (10.62) [17.01-55.88]z 44.22 (12.82) [9.23-55.88]z 45.98 (9.41) [28.67-55.88]z
Mental health 50.37 (9.93) [19.03-64.09] 49.86 (10.75) [19.03-64.09]z 50.29 (10.24) [21.85-64.09]z 51.01 (7.98) [33.11-64.09]z
PCSx 47.84 (9.69) [19.90-66.33] 48.65 (7.61) [28.38-61.05]z 46.14 (11.90) [19.90-66.33]z 48.37 (10.16) [20.35-61.66]z
MCSx 49.39 (10.11) [24.36-69.59] 48.93 (10.73) [26.66-62.63]z 49.34 (10.61) [24.36-69.59]z 50.29 (8.40) [34.74-67.46]z
FACT-Gk 86.86 (15.88) [31.0-108.0] 86.69 (15.90) [43.67-107.0]z 86.62 (18.10) [31.0-108.0] 87.47 (13.08) [50.0-108.0]z
RSCL{
PSD 15.54 (11.14) [0-53.62] 16.00 (12.05) [0-53.62] 15.39 (11.43) [0-50.72] 14.86 (9.10) [0-33.33]
SF-36 indicates Short-Form 36 Health Survey; PCS, Physical Component Score; MCS, Mental Component Score; FACT-G, Functional Assessment for Cancer
Therapy-General; RSCL, Rotterdam Symptom Checklist; PSD, Physical SymptomDistress; SD, standard deviation; HSCT, hematopoietic stem cell transplantation.
Data presented are mean (SD) [range] at time of study enrollment.
* Years post-HSCT were grouped to the nearest year including all observations  6 months, observations at exactly 6 months were rounded up.
y Normed to the 1998 US healthy population: M ¼ 50, SD ¼ 1023.
z Missing cases.
x n ¼ 167.
k n ¼ 168, reference values for 1998 US healthy population of adults M ¼ 80.1, SD ¼ 18.128.
{ Transformed to 0 to 100 scale; scores <10 suggest “low” symptom distress (eg, healthy population) and >15 suggest “high” symptom distress (ie, active
treatment).
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controlling for demographic and clinical covariates, receiving
systemic immunosuppression for the treatment of cGVHD at
any point post transplantation signiﬁcantly predicted im-
pairments in physical health (B ¼ 2.85, P < .001). In addi-
tion, symptom distress predicted physical health differently
based on the level of distress and time post transplantation
(interaction term B ¼ .03; P < .05). Relative to age-matched
normative values, survivors with high symptom distress re-
ported persistent impairments in physical health that
remained clinically meaningful up to 14 years post trans-
plantation, although the effect lessened over time (Figure 1).
In contrast, those with low symptom distress remained
within a range consistent with healthy population values,
despite a slight downward trend over time. Overall, survivors
with high symptom distress and/or those receiving systemic
immunosuppression experienced impairments in physical
health (Table 4).Mental Health
The unconditional model revealed there was no signiﬁ-
cant change in the mean trajectory of mental health (P  .05)
although the variance components were signiﬁcant (Table 3).
In the ﬁnal model (model 2), 3 time-varying predictors (ev-
idence of disease, immunosuppression, and physical symp-
tom distress) explained additional variability in baseline
mental health and the rate of change. After controlling for
demographic and clinical covariates, greater symptom
distress at any point following HSCT predicted signiﬁcantly
lower mental health (B ¼ .62; P < .001). Overall, survivors
with high symptom distress experienced clinically mean-
ingful impairments in mental health (Table 4).Health-Related Quality of Life
The unconditional model showed that there was no sig-
niﬁcant change in HRQL (P  .05) although the variance
components were signiﬁcant (Table 5). In the ﬁnal model
(model 2), 3 predictors (evidence of disease, immunosup-
pression, and symptom distress) explained additionalvariability in baseline HRQL and the rate of change. After
controlling for baseline demographic and clinical covariates,
physical symptom distress at any point post transplantation
predicted impairments in HRQL. Although HRQL scores were
lower for survivors with greater physical symptom distress,
scores were within the range for the healthy population,
suggesting no clinically meaningful impact from HSCT
(Table 4).Symptom Experience
Because physical symptom distress was found to be a
signiﬁcant predictor for all 3 outcomes, further descriptive
analyses were conducted. Themean PDS score for this sample
was high (>15) across the post-transplantation study interval
(Table 2). Seventy-three (42.7%) subjects reported high levels
of symptoms distress (>15), whereas 37 subjects (21.6%) re-
ported a moderate level of distress and 61 subjects (35.7%)
had low distress. Across time, the mean number of prevalent
symptoms ranged from 8 symptoms (standard deviation [SD]
 5) to 10 symptoms (SD 6.6). Physical symptoms that were
prevalent in a majority of subjects at almost every post
transplantation year included tiredness and lack of energy,
sore muscles, low back pain, difﬁculty sleeping, decreased
sexual activity, and difﬁculty concentrating. In the subgroup
of participants with high symptom distress, additional
symptoms that were prevalent in a majority of respondents
included headaches, dyspepsia, tingling hands or feet, hair
loss, burning or sore eyes, shortness of breath, and drymouth.
The high symptom distress subgroup reported a mean
number of prevalent symptoms that ranged across time from
12 (SD  3) symptoms to 14 (SD  4) symptoms.DISCUSSION
This study reveals that 3 or more years after HSCT,
physical health, mental health, and HRQL have generally
recovered to normative values and that these trajectories
remain stable. This observation that self-assessed health
status and HRQL are preserved 3 or more years post trans-
plantation supports previous studies suggesting that a full
Table 3
Final Hierarchical Linear Model for PCS and MCS
Factor PCS MCS
Unconditional
Model
Conditional Unconditional
Model
Conditional
Model 1 Final Model Model 1 Final Model
Coefﬁcient (SE) Coefﬁcient (SE) Coefﬁcient (SE) Coefﬁcient (SE) Coefﬁcient (SE) Coefﬁcient (SE)
Fixed effects
Intercept 48.41 (.78)* 60.12 (4.35)* 59.60 (3.57)* 49.83 (.97)* 48.76 (4.56)* 45.98 (3.54)*
Time (linear rate of change) .12 (.15) .88 (.42)y .78 (.36)y .13 (.17) .38 (.29) .29 (.22)
Intercept
Demographic and Clinical Covariates
Age .19 (.05)* .14 (.04)z .05 (.06) .11 (.04)y
Gender (ref.: male) 3.96 (1.52)z 2.27 (1.26) 2.04 (1.36) .29 (1.07)
Marital Status (ref.: no) .48 (1.38) .64 (1.12) 4.80 (1.45)z 3.56 (1.13)z
Ethnicity (ref.: Hispanic) 4.07 (1.39)z 4.06 (1.12)* 2.12 (1.47) 2.28 (1.15)y
Transplant risk status (ref.: low)
High/very high .38 (1.56) .63 (1.28) 3.39 (1.69)y 2.55 (1.31)
Intermediate 2.09 (1.59) 2.42 (1.28) 1.47 (1.68) .69 (1.30)
HCT-CI (ref.: 0)
3 Score 2.59 (1.49) 2.00 (1.21) 2.44 (2.15) 2.81 (1.60)
1 or 2 Score 1.40 (1.56) 1.30 (1.26) 6.28 (2.30)z 4.87 (1.73)z
Conditioning type (ref.: RIC) .60 (1.41) .38 (1.16) 2.78 (1.51) 2.47 (1.19)y
Time Varying Predictors
Evidence of Diseasex (ref.: none) 1.45 (.85)
Immune suppression (ref.: none) 2.85 (.79)*
Physical Symptom Distress .47 (.06)* .62 (.05)*
Linear (interaction)
Gender by time .59 (.29)y .47 (.25)
Physical symptom distress by time .03 (.01)y
HCT-CI by Time
3 Score 0.30 (0.40) 0.29 (0.31)
1 or 2 Score 1.19 (0.40)z 0.59 (0.31)
Variance components
Within-person 20.87 (1.76)* 21.27 (1.79)* 20.50 (1.50)* 33.98 (2.76)* 33.54 (2.69)* 30.11 (2.20)*
In intercept 62.80 (10.99)* 49.79 (9.69)* 27.16 (6.10)* 95.50 (17.13)* 75.07 (15.02)* 31.10 (7.53)*
In linear rate .69 (.39)y .37 (.33) 0 1.11 (.54)y .83 (.44)y 0
Covariance .22 (1.72) .22 (1.55) .88 (.76) 6.20 (2.87)* 4.84 (2.51) .03 (.81)
Goodness-of-ﬁt deviance 3652.2 3587.9 3472.7 3850.9 3783.3 3638.1
Model comparison (chi
square [df])
64.3 (10) 179.5 (14)* 67.6 (11) 212.8 (12)*
R2 at intercept 20.7% 56.8% 21.4% 67.4%
R2 at linear rate 46.4% 100% 25.2% 100%
PCS indicates Physical Component Score; MCS, Mental Component Score; SD, standard deviation; HSCT, hematopoietic stem cell transplantation; RIC, reduced-
intensity conditioning; HCT-CI, hematopoietic stem cell transplantationecomorbidity index.
Physical Symptom Distress was centered on the 3-year mean of 34.04 and age was centered on the 3-year mean of 43.95. Intercept here means 3 years post
HSCT. Education was not signiﬁcant in the unconditional model.
* P < .001.
y P < .05.
z P < .01.
x Of those classiﬁed as having evidence of disease, 5 (14.7%) had achieved a CR but were continuing a course of disease speciﬁc treatment.
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novel insight provided by this study is that the trajectory
remains stable, suggesting that treatment with allogeneic
HSCT, although expensive, potentially risky, and burden-
some, has the potential to return survivors to a health state
that is comparable to healthy population values.
Although a majority of HSCT survivors are likely to ach-
ieve a satisfactory recovery in terms of health status and
HRQL, it has been argued previously that “complacency is not
an option” [41]. Substantial variability in health status and
HRQL existed among survivors, for which physical symptom
distress was a signiﬁcant predictor. Respondents with higher
symptom distress reported a physical and mental health
status that was signiﬁcantly lower than healthy population
values, and this difference was also clinically meaningfully.
Moreover, in survivors with high symptom distress, the tra-
jectory of physical health reﬂected impairment through and
beyond the ﬁrst decade post transplantation. These ﬁndings
support systematic screening of health status to identify
HSCT survivors at risk for long-term impairments.These ﬁndings suggest that symptom distress, as a
symptomatic late effect of HSCT, is an important target for
clinical intervention. Other investigators have noted the
importance of post-transplantation symptom distress in ac-
counting for impairments in a range of outcomes [42-45].
Although the nature of the symptoms described by survivors
in the current study (fatigue, limited sexual interest, difﬁ-
culty sleeping, and difﬁculty concentrating) have been well
documented [46], this study is the ﬁrst to characterize the
contribution that symptom distress makes to clinically
signiﬁcant impairments in health status and HRQL in trans-
plantation survivors over time. Factors that may contribute
to symptom distress in allogeneic HSCT survivors include
post-transplantation comorbid conditions, late treatment
effects, cGVHD, and side effects of immunosuppression [15].
Consistent with ﬁndings from previous studies [16,17],
treatment with immunosuppression also predicted signiﬁ-
cant impairments in physical health for survivors. The ﬁnd-
ings from the present study suggest that subgroups of
transplant recipients, including those experiencing higher
Figure 1. Trajectories of predicted PCS scores. RSCL physical symptom distress level was classiﬁed based on linearly transformed scores across 553 observations.
High: n ¼ 261, Low: n ¼ 189.
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are coping with signiﬁcant impairments, suggesting a need
for aggressive supportive care management. Additional
studies to more fully characterize both the symptom expe-
rience and its underlying causal pathways are needed toTable 4
Adjusted Means for PCS, MCS, and FACT-G
Factor Adjusted Means
PCS MCS FACT-G
Physical symptom distress*
High 43.7 (5.5) 44.2 (5.7) 78.1 (8.4)
Med 49.2 (3.2) 51.7 (3.1) 89.5 (2.1)
Low 53.2 (4.0) 54.6 (3.7) 95.5 (3.5)
Occurrence of immunosuppression
No 50.0 (5.4)
Yes 46.0 (6.1)
Age
Older (>55) 45.2 (5.6) 52.9 (6.7)
Younger (30) 54.7 (4.9) 50.1 (4.0)
Ethnicity
Hispanic 50.8 (5.5) 51.0 (6.7)
Non-Hispanic 46.2 (5.7) 47.6 (5.6)
Transplantation type
RIC 51.2 (6.7)
Myeloablative 47.3 (5.4)
Marital status
Married 50.5 (6.1)
Nonmarried 47.3 (6.6)
Comorbidity Index Score
0 47.5 (7.2)
1-2 54.2 (3.5)
>3 48.1 (6.0)
PCS indicates Physical Component Score; MCS, Mental Component Score;
FACT-G, Functional Assessment for Cancer Therapy-General; RIC, reduced-
intensity conditioning.
* Theoretical range 0 to 100. A score of < 10 was considered “low” (eg,
healthy population), 10 to 15 as “mild/moderate” (ie, disease free popula-
tion, newly diagnosed), and>15 as “high” (ie, active treatment, high burden
cancer type).inform the development of tailored supportive care in-
terventions for transplantation survivors.
In addition, survivors who were older and non-Hispanic
reported signiﬁcantly lower levels of physical health. These
results are consistent with the ﬁndings of another investi-
gator who also observed that these 2 demographic factors
were associated with limitations in physical health post
transplantation [16]. The association between ethnicity and
physical health is somewhat in contrast to other studies that
have described an association between individuals of His-
panic ethnicity and inferior HSCT outcomes [47,48]. It should
be noted that a majority of Hispanic participants in the cur-
rent study were residing outside the United States This factor
may have biased our sample towards Hispanic respondents
with a level of social support or ﬁnancial resources that
facilitated their travel to the United States for the HSCT. In
addition, the return to an ethnically homogeneous commu-
nity during post-transplantation reintegration might pro-
duce salutary effects on aspects of self-assessed health for
long-term survivors [49,50]. The observed association be-
tween being Hispanic and more favorable physical health
should be explored in future studies using samples that are
sufﬁciently large to permit subgroup analysis.
Relative to mental health, survivors who were younger,
unmarried, non-Hispanic, received reduced-intensity con-
ditioning, and who proceeded into HSCT without comor-
bidities reported less favorable mental health. Although
these predictors achieved statistical signiﬁcance in the
model, their clinical relevance is uncertain. Except for
physical symptom distress, between-group differences in
adjusted means for mental health based on age, marital
status, race/ethnicity, transplantation conditioning, and co-
morbidity did not exceed theminimally important difference
of 3 points (Table 4).
These study results should be interpreted in light of
several limitations, including that we were underpowered
for a variety of subgroup analyses. Further, the inclusion of
Table 5
Final Hierarchical Linear Model for FACT-G
Factor FACT-G
Unconditional Conditional
Model Model 1 Final Model
Coefﬁcient (SE) Coefﬁcient (SE) Coefﬁcient (SE)
Fixed effects
Intercept 87.65 (1.39)* 95.61 (7.80)* 89.87 (5.48)*
Time (linear rate of change) .39 (.25) 1.00 (.41)y .20 (.31)
Intercept
Demographic and Clinical Covariates
Age .13 (.10) .02 (.07)
Gender (ref.: male) 3.01 (2.36) .09 (1.65)
Marital status (ref.: no) 2.19 (3.00) 2.38 (2.21)
Ethnicity (ref.: Hispanic) .92 (2.53) .89 (1.75)
Transplant risk status (ref.: low)
High/very high 4.71 (2.88) 2.43 (2.03)
Intermediate 1.53 (2.91) .57 (2.02)
HCT-CI (ref.: 0)
3 Score .19 (2.74) .86 (1.91)
1 or 2 Score 3.47 (2.85) 3.75 (1.98)
Conditioning type (ref.: RIC) 2.25 (2.57) 2.27 (1.81)
Time Varying Predictors
Evidence of diseasez (ref.: none) 1.09 (1.22)
Immune suppression (ref.: none) 1.23 (1.18)
Physical Symptom Distress 1.03 (.06)*
Linear (interaction)
Marital Status by Time 0.99 (0.51) 0.21 (0.37)
Variance components
Within-person 48.99 (4.07)* 48.63 (4.03)* 37.05 (3.12)*
In intercept 221.56 (35.44)* 203.99 (34.59)* 100.03 (19.08)*
In linear rate 2.44 (1.05)x 2.17 (1.04)y .55 (.61)
Covariance 9.29 (5.66) 7.84 (5.68) 3.43 (3.13)
Goodness-of-ﬁt deviance 4180.3 4141.4 3881.4
Model comparison (chi square [df]) 38.9 (10) 298.9 (13)*
R2 at intercept 7.9% 54.9%
R2 at linear rate 11.1% 77.5%
FACT-G indicates Functional Assessment for Cancer Therapy-General; SD, standard deviation; RIC, reduced-intensity conditioning; HCT-CI, hematopoietic stem
cell transplantationecomorbidity index; SE, standard error; HSCT, hematopoietic stem cell transplantation; df, degrees of freedom.
Physical Symptom Distress was centered on the intercept mean of 34.04 and age was centered on the intercept mean of 43.95. Intercept here means 3 years post
HSCT. Education was not signiﬁcant in the unconditional model.
* P < .001.
y P < .05.
z Of those classiﬁed as having evidence of disease, 5 (14.7%) had achieved a CR but were continuing a course of disease speciﬁc treatment.
x P < .01.
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might have reﬁned our understanding of the factors that
predict variation in transplantation recovery. We gauged the
presence and severity of cGVHD by scoring the intensity of
immunosuppression rather than clinical grading of cGVHD
because such grading was not consistently available for all
subjects at all time points. Notably, intensity of immuno-
suppression was a signiﬁcant predictor of impairment in
physical health, but not of mental health or HRQL. Future
studies should make every effort to incorporate objective
clinical grading of cGVHD using the National Institutes of
Health Criteria [51], in addition to measurement of intensity
of immunosuppression. We also cannot exclude a possibility
that response shift explains some of the ﬁndings observed in
this study. When response shift occurs, respondents change
their internal standards, values, and conceptualizations of
HRQL over time as part of their accommodation to the long-
term physical consequences of serious chronic or life-
threatening illness [52]. Thus, as a result of response shift,
respondents may rate their health status or quality of life as
satisfactory, despite objective evidence of adverse clinical
changes [53-55]. There has been only limited study of
response shift in cancer survivors more generally, and future
research is needed to determine whether this phenomenonaccounts for some of the observed effects in HRQL studies in
allogeneic HSCT survivors.
At the same time, the strengths of our study include the
focus on allogeneic HSCT recipients, rather than a mixed sam-
ple of allogeneic and autologous recipients. Other strengths
include the longitudinal design, inclusion of an ethnically
and linguistically diverse sample, the control of important
biomedical covariates, limited sample attrition, and the inclu-
sion of transplantation survivors with evidence of disease
recurrence, a group that has to date, been understudied.
Clinically, our results underscore the importance of
aggressive symptom management in optimizing health
outcomes in long-term survivors; those receiving more
intensive immunosuppression are an important subgroup to
target for interventions. Careful monitoring of symptom
distress and its impact on daily functioning is an important
supplement to HRQL measurement. One might argue that
symptom distress is not reliably assessed by providers [56],
supporting the importance of incorporating patient-reported
outcomes into routine practice.
Lastly, the ﬂat trajectory in health status and HRQL post
transplantation suggests both an opportunity and a risk for
individuals facing allogeneic HSCT. Additional studies are
needed to deﬁne factors that contribute to physical symptom
M.F. Bevans et al. / Biol Blood Marrow Transplant 20 (2014) 387e395394distress post transplantation and to test interventions that
can favorably redirect the trajectory of post-transplantation
recovery for those at risk for adverse outcomes.ACKNOWLEDGMENTS
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